Engagement. Expertise. Results.
CenExel CBH has been leading the CNS clinical research industry for 25 years.
CenExel CBH is a provider of comprehensive behavioral health services in the Baltimore-Washington metropolitan area. We are staffed with qualified mental health professionals including psychiatrists, psychologists, social workers, and nurses. We have conducted over 350 clinical trials at our state-of-the-art research facilities located in Gaithersburg, Maryland. We are a CenExel Center of Excellence, assuring unparalleled patient engagement, staff expertise, and valuable results.
CenExel CBH has an extensive background of hundreds of clinical trials.
CenExel CBH merged all inpatient and outpatient facilities into a 20,000 square foot space.
CenExel CBH has a proven record in recruiting, exceeding 100% of patient target.
CenExel CBH leadership guides the CenExel Psychiatric Scientific Advisory Board.
CenExel CBH trains staff via pilot studies and diverse methodology training
CenExel CBH serves a region of 6.2M people with a large demographic diversity.
Robert E Litman, MD
Medical Director and Principal Investigator
301-251-4702, ext 3203
Robert E. Litman, M.D., is the Medical Director and Principal Investigator for all clinical trials at CenExel CBH. He developed his interest in the treatment of schizophrenia at Massachusetts General Hospital, where he completed his residency in Psychiatry. Shortly thereafter, he joined the Experimental Therapeutics Branch, National Institute of Mental Health, NIH, as a Senior Staff Fellow remaining at NIH until 1995, where he continued to pursue his interest in schizophrenia, including investigating the effects of atypical neuroleptics biological and genetic markers in schizophrenia, as well as the development of better combination therapies for schizophrenia using the alpha-2 antagonist idazoxan. After leaving the NIH, he formed his own clinical trials research organization, first in conjunction with area hospitals, and then as a free-standing inpatient and outpatient clinical research organization now known as CenExel CBH. Since then he has conducted over 300 Phase I-IV clinical trials and has participated in many of the important advances in pharmacotherapy of schizophrenia and other brain disorders.
Dr. Litman has an extensive background in psychopharmacology, the evaluation and treatment of schizophrenia, bipolar, major depression, anxiety, and Alzheimer disease. He serves as a consultant in psychopharmacology to many area hospitals and group practices, has over 30 academic publications, and frequently speaks about new advances in the field of psychopharmacology, and on the current issues regarding drug development for psychiatric illness. He is currently an Associate Professor of Psychiatry at Georgetown University Medical School, (where he teaches and trains Psychiatry residents) and a Fellow and Diplomate of the American Board of Psychiatry and Neurology and Diplomate, Added Qualifications in Geriatric Psychiatry.
Elia Acevedo-Diaz, MD
301-251-4702, ext 3218
Elia E. Acevedo-Diaz, M.D., developed her interest in the research and development of new therapeutics for psychiatric disorders at the National Institutes of Health, Intramural Program. She joined the Experimental Therapeutics and Pathophysiology Branch of the National Institute of Mental Health (NIMH) as a clinical fellow after completing 3 years of psychiatry residency at Boston University. During her time at the NIMH, she participated in important advances in pharmacotherapy of treatment resistant depression. She has an extensive background in psychopharmacology and the evaluation and treatment of mood disorders, anxiety, and schizophrenia. She has several academic publications and is a Diplomate of the American Board of Psychiatry and Neurology.
2018 – 2020 Statistics
Looking for a Center of Excellence?
Reaching new heights in clinical research
Our Centers of Excellence provide unparalleled medical and scientific support in the design and execution of clinical trials. Our attention to detail assures quality, reliable results, and has helped CenExel to consistently achieve and exceed patient recruitment goals. We deliver the expertise, engagement, and results to ensure our clients achieve their clinical research goals.
To speed up study implementation, we provide centralized budgeting and contracting for sponsors engaging multiple Centers of Excellence. The geographic diversity of our network offers strong access to roughly 35 million subjects while our broad therapeutic expertise enables a variety of clinical trial strengths.
Top Therapeutic Areas of Expertise
Acute Post-op Pain:
Open Hernia Repair
Wisdom Tooth Extraction
Healthy Volunteer (all ages)
CenExel ACMR conducts Phase I (first-in-human) through Phase IV clinical trials in Psychiatry and Neurology and other medical indications.
CenExel ACT has been dedicated to assisting pharmaceutical companies find new cures to help patients better manage their healthcare for over two decades.
CIT has over 40 years of knowledge in conducting Phase I to Phase IV clinical studies in partnership with major pharmaceutical sponsors. Our well-trained teams provide accurate and timely results for every clinical trial conducted in areas such as neurology and psychiatry.
CenExel RCA has extensive experience with inpatient and outpatient clinical trials, ranging from pediatric to geriatric populations, with special emphasis on Phase I-III mental health and Central Nervous System (CNS) disorders, substance use disorders, and sleep studies.
Specializing in Central Nervous System (CNS) disorders for more than 26 years, CenExel CBH works with individuals with psychiatric illnesses in the greater DC-Baltimore metro area.